FDA advisory committee thumbs up on Mesoblast's Ryoncil
Aug. 13, 2020 5:05 PM ETMesoblast Limited (MESO)By: Douglas W. House, SA News Editor1 Comment
• The FDA's Oncologic Drugs Advisory Committee voted 8-2 backing approval of Mesoblast Limited's (NASDAQ:MESO) Ryoncil (remestemcel-L) (ex-vivo culture-expanded adult human mesenchymal stromal cells suspension for intravenous infusion) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
• The positive vote surprised some observers considering the issues cited in the review team's briefing document.
• Trading, suspended this morning pending the outcome of the meeting, has yet to resume.
Congrats all especially The prof and board, what a moment for stem cell as well!
- Forums
- ASX - By Stock
- MSB
- Ryoncil: ODAC/FDA Meeting Discussion
Ryoncil: ODAC/FDA Meeting Discussion, page-1684
-
- There are more pages in this discussion • 363 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $4.501M | 3.817M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 24941 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 116868 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 14417 | 1.165 |
34 | 53676 | 1.160 |
13 | 36820 | 1.155 |
15 | 114053 | 1.150 |
17 | 208918 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 77478 | 9 |
1.175 | 73011 | 11 |
1.180 | 77071 | 11 |
1.185 | 13924 | 3 |
1.190 | 44000 | 4 |
Last trade - 14.18pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online